Targeting ADRB2 Enhances Sensitivity of Non-Small Cell Lung Cancer to VEGFR2 Tyrosine Kinase Inhibitors

Investigators suggested that treatment with vascular endothelial growth factor receptor 2 (VEGFR2)-tyrosine kinase inhibitors upregulated ADRB2 expression in NSCLC cells.